Form 4: Catalyst Pharmaceuticals Executive Brian Elsbernd Reports Stock Transactions

Brian Elsbernd, Chief Compliance/Legal Officer at Catalyst Pharmaceuticals, reported the vesting of restricted stock units and subsequent tax withholding.

Summary

• Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, reported transactions involving the company's stock.
• On December 9, 2024, 7,067 restricted stock units vested, converting into common stock.
• A total of 1,720 shares were withheld by the company to cover tax obligations related to the vesting.
• Following these transactions, Elsbernd directly owns 176,524 shares of Catalyst Pharmaceuticals common stock.
• Elsbernd also holds 1,087,943 restricted stock units.

Sentiment

Score: 7

Explanation: The document is a routine filing related to executive compensation. It is neutral in nature and expected, therefore the sentiment is slightly positive due to the vesting of stock units.

Industry Context

This is a routine SEC Form 4 filing, which is standard practice when company insiders trade company stock. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• SEC Form 4 filings are a standard requirement for all publicly traded companies in the United States.
• The vesting of restricted stock units is a common form of executive compensation, aligning management interests with shareholder value.
• The tax withholding process is also standard practice to cover income tax liabilities arising from the vesting of stock units.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The vesting of stock units aligns the executive's interests with the company's performance.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock transaction, restricted stock units, insider trading, executive compensation, Brian Elsbernd, CPRX